Our Science

What are T Cell-Engagers?

T cell-engagers (TCEs) are bispecific antibodies that simultaneously target CD3 on T cells and specific antigens on the cell surface to enable T cell-mediated depletion of the target cell. BCMA-targeted T cell-engagers are being investigated as a precision approach for severe inflammatory and autoimmune diseases by eliminating pathogenic B cells and plasma cells. By redirecting a patient’s own T cells towards BCMA-expressing plasma cells, clinical data suggests these agents may reduce inflammation, improve organ function impacted by disease, and in some cases, enable an immune reset marked by durable drug-free remission without ongoing immunosuppression.

Gamgertamig (OM336):

Gamgertamig is a BCMAxCD3 bispecific TCE designed to potentially enable rapid, deep, and durable B cell and plasma cell depletion following a limited subcutaneously administered treatment course. We believe that B cell and plasma cell depleting TCEs could enable a paradigm shift in the treatment of autoimmune diseases from chronic symptom control to potentially durable immune reset. Based on encouraging Phase 1/2 clinical data in >60 patients, a short course of subcutaneous gamgertamig has the potential to show:

• Rapid and deep B cell and plasma cell depletion
• Transformative efficacy in immune-mediated diseases
• Tolerable safety profile, with minimal CRS and no ICANS

Discover the indications currently being evaluated for gamgertamig in our Pipeline section and explore the supporting scientific research in our Publications section.

Preclinical portfolio:

Behind our lead program, we are advancing a set of discovery programs targeting additional aspects of B cell biology. These programs probe unique subsets of B cells that may prove key to achieving longer remissions for patients with certain diseases.